Plot No.367, Abhey Pur, Industrial Area Phase-1, Panchkula, Haryana 134109
Don't miss out on this limited-time offer to join our successful PCD Pharma network. Fill in your details below and our team will get in touch with you to discuss the best franchise opportunities tailored to your needs.
Formoterol (6mcg) + Fluticasone Propionate (100mcg)
Therapeutic Category
Asthma, Pulmonary, Respiratory
Dosage Form
Inhaler
Packaging Type
carton with leaflet
Packaging
120 Metered Dose
Price
₹1/-
High-resolution images and Product visuals
Product overview and usage information
Detailed information and research documents
Flutialfa F 100 Inhaler is a combination medication designed to manage and treat asthma and chronic obstructive pulmonary disease (COPD). It combines Formoterol, a long-acting beta-agonist (LABA), with Fluticasone Propionate, a potent corticosteroid. Formoterol works by relaxing the muscles in the airways, improving airflow and reducing symptoms of wheezing and shortness of breath. Fluticasone Propionate helps reduce inflammation in the airways, making breathing easier and preventing asthma attacks and COPD exacerbations.
This inhaler is specifically indicated for patients who require a combination of a long-acting bronchodilator and a corticosteroid for the long-term management of asthma or COPD. It is not intended for the immediate relief of acute symptoms but is used as part of a long-term maintenance treatment plan.
Common side effects include headache, throat irritation, and hoarseness; rare effects may include oral thrush and paradoxical bronchospasm.
For the long-term control of Asthma and Chronic Obstructive Pulmonary Disease (COPD).
This inhaler is not for acute asthma attacks; rinse mouth after use to avoid infections.
Store in a cool, dry place, away from direct sunlight and heat. Keep out of reach of children.
Composition : Budesonide (0.5mg) Respule
Composition : Budesonide (100mcg) Inhaler
Composition : Budesonide (200mcg) Inhaler
Composition : Budesonide (400mcg) + Formoterol (6mcg) Rota Caps
Composition : Budesonide (0.5mg) + Formoterol (20mcg) Respule
Composition : Formoterol (20mcg) + Budesonide (0.5mg) Respule
Composition : Glycopyrronium (25mcg) + Formoterol (12mcg)+ Budesonide (400 mcg) Rota Capsule
Composition : Formoterol (6mcg) + Budesonide (400mcg) Inhaler
This catalog is a digital representation of the Cafoli Lifecare portfolio and is intended for use by authorized pharmaceutical distributors and PCD franchise partners.
Formoterol 6 mcg + Fluticasone Propionate 100 mcg Inhaler is a combination inhalation therapy used for the long-term management of asthma and Chronic Obstructive Pulmonary Disease (COPD). Formoterol is a long-acting beta-2 agonist (LABA) that helps relax airway muscles and improves breathing. Fluticasone Propionate is an inhaled corticosteroid (ICS) that reduces airway inflammation and helps prevent asthma symptoms and COPD exacerbations. This combination provides effective control of respiratory symptoms and improves lung function, making it a valuable product in the pulmonology and respiratory care segment.
Medical distributors and wholesalers can benefit from strong and recurring demand from pulmonologists, chest physicians, pediatricians, and general practitioners. As asthma and COPD are chronic respiratory diseases requiring long-term maintenance therapy, this product ensures regular prescriptions, repeat purchases, and sustainable business growth.
Yes, Cafoli Lifecare offers PCD pharma pharma franchise opportunities in respiratory, pulmonology, and inhalation therapy segments with monopoly rights, quality manufacturing standards, and reliable supply support for distributors and medical agencies.
Wholesalers and medical agencies benefit from high chronic disease prevalence, specialist-driven prescriptions, and long-term therapy adherence, making it a stable, high-value, and repeat-order pharmaceutical category when partnered with Cafoli Lifecare.
Medical distributors, stockists, and pharma professionals interested in respiratory and inhalation therapy products can contact Cafoli Lifecare to discuss product availability, pricing structure, and PCD pharma franchise opportunities in the pulmonology and respiratory care segment.